Clinical equipoise: an argument for expedited approval of the first small step toward an autonomous artificial pancreas

Click to increase image sizeClick to decrease image size

Financial & competing interests disclosure

SA Weinzimer is a consultant for Lifescan/Animas, BD, Novo Nordisk and Insuline and a speaker for Eli Lilly. WV Tamborlane is a consultant for Medtronic, LifeScan/Animas and Novo Nordisk and a speaker for Novo Nordisk. This publication was made possible by CTSA grant numbers 5 KL2 RR024138, UL1 RR024139 and P30 DK45735 from the National Center for Research Resources (NCRR) and the National Center for Advancing Translational Science (NCATS), components of the NIH and NIH roadmap for Medical Research. Its contents are solely the responsibility of the authors and do not necessarily represent the official view of the NIH. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.